The Effect of Medical Cannabis on Anxiety and Depression
DOI:
https://doi.org/10.55677/IJCSMR/V4I11-01/2024Keywords:
Cannabis, Depression, AnxietyAbstract
In December 2020, the United Nations removed medical cannabis (MC) from Schedule 4 of the 1961 UN Convention on Narcotic Drugs following a recommendation by the World Health Organization (WHO) on its medical potential to pave the way for the reduction of regulatory barriers for research (United Nations, 2020). Some of the medical indications for MC include but are not limited to rare seizure disorders, symptomatic treatment of nausea and vomiting, insomnia, pain, loss of appetite, anxiety, and post-traumatic stress disorder (PTSD), as well as glaucoma, Huntington’s Disease, dystonia, and Parkinson’s Disease (Klumpers & Thacker, 2019). In countries like the United States, MC prescriptions are on the rise for various medical indications, especially in symptomatic treatment of nausea and vomiting, loss of appetite, and pain among oncology patients (Corroon et al., 2019; Vinette et al., 2022).
References
Ayisire, O. E., Okobi, O. E., Adaralegbe, N. J., Adeosun, A. A., Sood, D., Onyechi, N. P., Agazie, O., Shittu, H. O., Akinsola, Z., Nnaji, C. G., Owolabi, O. J., Umeh, N. J., Imobighe, I. C., Adedoyin, A. M., & Usman, M. (2022). The use of cannabis and its effects on postpartum depression. Cureus. https://doi.org/10.7759/cureus.27926
Bahorik, A. L., Sterling, S. A., Campbell, C. I., Weisner, C., Ramo, D., & Satre, D. D. (2018). Medical and non-medical marijuana use in depression: Longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. Journal of Affective Disorders, 241, 8–14. https://doi.org/10.1016/j.jad.2018.05.065
Bar-Lev Schleider, L., Mechoulam, R., Sikorin, I., Naftali, T., & Novack, V. (2022). Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: A prospective study. Frontiers in Medicine, 9, 827849. https://doi.org/10.3389/fmed.2022.827849
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226. https://doi.org/10.1038/npp.2011.6
Berger, M., Amminger, G. P., & McGregor, I. S. (2022). Medicinal cannabis for the treatment of anxiety disorders. Australian Journal of General Practice, 51(8), 586–592. https://doi.org/10.31128/AJGP-04-21-5936
Berger, M., Li, E., & Amminger, G. P. (2020). Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Reports, 13(10), e235307. https://doi.org/10.1136/bcr-2020-235307
Bidwell, L. C., Martin-Willett, R., Skrzynski, C., Lisano, J., Ortiz Torres, M., Giordano, G., Hutchison, K. E., & Bryan, A. D. (2024). Acute and extended anxiolytic effects of cannabidiol in cannabis flower: A quasi-experimental ad libitum use study. Cannabis and Cannabinoid Research, 9(4), 1015–1027. https://doi.org/10.1089/can.2023.0187
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. The Lancet Psychiatry, 6(12), 995–1010.
https://doi.org/10.1016/S2215-0366(19)30401-8
Corroon, J., Sexton, M., & Bradley, R. (2019). Indications and administration practices amongst medical cannabis healthcare providers: A cross-sectional survey. BMC Family Practice, 20(1), 174. https://doi.org/10.1186/s12875-019-1059-8
Crichton, M., Dissanayaka, T., Marx, W., Gamage, E., Travica, N., Bowers, A., Isenring, E., Yates, P., & Marshall, S. (2024). Does medicinal cannabis affect depression, anxiety, and stress in people with cancer? A systematic review and meta-analysis of intervention studies. Maturitas, 184, 107941.
https://doi.org/10.1016/j.maturitas.2024.107941
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Filho, A. S., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., & Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology, 25(1), 121–130. https://doi.org/10.1177/0269881110379283
Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N. S., & Kapur, D. (2008). Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ, 336(7637), 199–201.
https://doi.org/10.1136/bmj.39429.619653.80
Klier, C. M., De Gier, C., Felnhofer, A., Laczkovics, C., & Amminger, P. G. (2020). A case report of cannabidiol treatment of a Crohn’s disease patient with anxiety disorder. Journal of Clinical Psychopharmacology, 40(1), 90–92.
https://doi.org/10.1097/JCP.0000000000001152
Klumpers, L. E., & Thacker, D. L. (2019). A brief background on cannabis: From plant to medical indications. Journal of AOAC INTERNATIONAL, 102(2), 412–420. https://doi.org/10.5740/jaoacint.18-0208
Lapham, G. T., Matson, T. E., Carrell, D. S., Bobb, J. F., Luce, C., Oliver, M. M., Ghitza, U. E., Hsu, C., Browne, K. C., Binswanger, I. A., Campbell, C. I., Saxon, A. J., Vandrey, R., Schauer, G. L., Pacula, R. L., Horberg, M. A., Bailey, S. R., McClure, E. A., & Bradley, K. A. (2022). Comparison of medical cannabis use reported on a confidential survey vs documented in the electronic health record among primary care patients. JAMA Network Open, 5(5), e2211677. https://doi.org/10.1001/jamanetworkopen.2022.11677
Leung, J., Chan, G., Stjepanović, D., Chung, J. Y. C., Hall, W., & Hammond, D. (2022). Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology, 239(5), 1509–1519. https://doi.org/10.1007/s00213-021-06047-8
Malik, Z., Bayman, L., Valestin, J., Rizvi-Toner, A., Hashmi, S., & Schey, R. (2016). Dronabinol increases pain threshold in patients with functional chest pain: A pilot double-blind placebo-controlled trial: Dronabinol increases pain threshold in patients. Diseases of the Esophagus, n/a-n/a.
https://doi.org/10.1111/dote.12455
Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008). Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. The Journal of Pain, 9(3), 254–264. https://doi.org/10.1016/j.jpain.2007.10.018
Pini, L. A., Guerzoni, S., Cainazzo, M. M., Ferrari, A., Sarchielli, P., Tiraferri, I., Ciccarese, M., & Zappaterra, M. (2012). Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. The Journal of Headache and Pain, 13(8), 677–684. https://doi.org/10.1007/s10194-012-0490-1
Poli, P., Crestani, F., & Salvadori, C. (2018). Medical cannabis in patients with chronic pain: Effect on pain relief, pain disability, and psychological aspects. A prospective non-randomized single-arm clinical trial. LA CLINICA TERAPEUTICA, 3, 102–107. https://doi.org/10.7417/T.2018.2062
Portenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., & Fallon, M. T. (2012). Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. The Journal of Pain, 13(5), 438–449. https://doi.org/10.1016/j.jpain.2012.01.003
Sachedina, F., Chan, C., Damji, R. S., & De Sanctis, O. J. (2022). Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study. Psychiatry Research, 313, 114573. https://doi.org/10.1016/j.psychres.2022.114573
Sexton, M., Cuttler, C., Finnell, J. S., & Mischley, L. K. (2016). A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy. Cannabis and Cannabinoid Research, 1(1), 131–138. https://doi.org/10.1089/can.2016.0007
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal, 23(1), 18–041. https://doi.org/10.7812/TPP/18-041
Shannon, S., & Opila-Lehman, J. (2016). Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report. The Permanente Journal, 20(4), 16–005. https://doi.org/10.7812/TPP/16-005
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008). Nabilone for the treatment of pain in fibromyalgia. The Journal of Pain, 9(2), 164–173. https://doi.org/10.1016/j.jpain.2007.09.002
Stanciu, C. N., Brunette, M. F., Teja, N., & Budney, A. J. (2021). Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: A systematic review. Psychiatric Services, 72(4), 429–436. https://doi.org/10.1176/appi.ps.202000189
Sznitman, S. R. (2017). Do recreational cannabis users, unlicensed and licensed medical cannabis users form distinct groups? International Journal of Drug Policy, 42, 15–21.
https://doi.org/10.1016/j.drugpo.2016.11.010
Toth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012). An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain, 153(10), 2073–2082. https://doi.org/10.1016/j.pain.2012.06.024
United Nations. (2020). UN commission reclassifies cannabis, yet still considered harmful. https://news.un.org/en/story/2020/12/1079132
Vinette, B., Côté, J., El-Akhras, A., Mrad, H., Chicoine, G., & Bilodeau, K. (2022). Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: A scoping review. BMC Cancer, 22(1), 319. https://doi.org/10.1186/s12885-022-09378-7
Waissengrin, B., Urban, D., Leshem, Y., Garty, M., & Wolf, I. (2015). Patterns of use of medical cannabis among Israeli cancer patients: A single institution experience. Journal of Pain and Symptom Management, 49(2), 223–230.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Clinical Science and Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
